Morfina Cloridrato Monico (Morphine Hydrochloride Trihydrate)

• Morphine acts on the central nervous system to relieve pain in several clinical settings.
• Severe acute pain: provides rapid analgesia for trauma or injury.
• Post‑operative pain: controls pain after surgical procedures.
• Cancer‑related pain: manages persistent pain associated with malignant disease.
• Chronic severe pain requiring opioid therapy: offers long‑term relief when other analgesics are insufficient.

• Morphine Hydrochloride Trihydrate binds selectively to mu‑opioid receptors in the brain, spinal cord and peripheral nervous system. Activation of these G‑protein‑coupled receptors inhibits adenylate cyclase, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and diminished transmission of nociceptive signals, thereby producing analgesia.

Morphine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting
• Constipation
• Drowsiness or sedation
• Dizziness or light‑headedness
• Pruritus (itching)
• Sweating or flushing

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension or cardiovascular collapse
• Adrenal insufficiency
• Seizures
• Anaphylactic or hypersensitivity reactions
• Physical dependence, tolerance, and addiction

• When prescribing or handling morphine, several safety considerations are essential.
• Assess pain severity and opioid requirement: ensure the indication justifies strong opioid use.
• Evaluate respiratory function: monitor for depression, especially in opioid‑naïve patients.
• Review patient opioid tolerance: adjust dosing for those with prior opioid exposure.
• Monitor for signs of dependence or misuse: implement appropriate risk‑mitigation strategies.
• Adjust dose in renal or hepatic impairment: consider reduced clearance.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Morphine interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid)

• Central nervous system depressants (e.g., benzodiazepines, barbiturates): risk of profound sedation and respiratory depression.
• Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension or serotonin syndrome.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase morphine plasma levels.
• Respiratory depressants (e.g., anesthetic agents): additive effect on breathing.
• Drugs that lower seizure threshold: may increase seizure risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine effectiveness.
• Diuretics: can enhance orthostatic hypotension.
• Antihistamines and anticholinergics: may increase sedation and anticholinergic side effects.
• Certain antidepressants (e.g., SSRIs): may modestly affect opioid metabolism.
• Anticonvulsants: may alter seizure threshold when combined with morphine.